Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
Longboard Pharmaceuticals (Nasdaq: LBPH) has announced it will release its second quarter 2024 financial results and provide a corporate update on August 1, 2024. The update will include topline Phase 1 single ascending dose (SAD) data for LP659, their centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator. A conference call and webcast will be held at 4:30pm ET (1:30pm PT) on the same day.
Investors can access the live webcast through the Events & Presentations section of Longboard's investor page. A replay will be available shortly after and archived for at least 30 days. Participants can join via webcast or dial-in using the provided links and conference ID.
Longboard Pharmaceuticals (Nasdaq: LBPH) ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 e fornirà un aggiornamento aziendale il 1 agosto 2024. L'aggiornamento includerà i dati preliminari della Fase 1 relativi a dosi singole ascendenti (SAD) per LP659, il loro modulatore selettivo del recettore della sfingosina-1-fosfato (S1P) ad azione centrale. Una conferenza telefonica e una trasmissione in diretta saranno tenute alle 4:30pm ET (1:30pm PT) nello stesso giorno.
Gli investitori possono accedere alla trasmissione in diretta attraverso la sezione Eventi e Presentazioni della pagina per gli investitori di Longboard. Una registrazione sarà disponibile poco dopo e archiviata per almeno 30 giorni. I partecipanti possono unirsi tramite webcast o chiamata, utilizzando i collegamenti e l'ID conferenza forniti.
Longboard Pharmaceuticals (Nasdaq: LBPH) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 y proporcionará una actualización corporativa el 1 de agosto de 2024. La actualización incluirá datos preliminares de la Fase 1 sobre dosis únicas ascendentes (SAD) para LP659, su modulador selectivo del receptor de esfingosina-1-fosfato (S1P) de acción central. Se llevará a cabo una llamada de conferencia y una transmisión web a las 4:30pm ET (1:30pm PT) el mismo día.
Los inversores pueden acceder a la transmisión en vivo a través de la sección de Eventos y Presentaciones de la página de inversores de Longboard. Una grabación estará disponible poco después y archivada por al menos 30 días. Los participantes pueden unirse a través de la transmisión web o llamando utilizando los enlaces y el ID de conferencia proporcionados.
롱보드 제약(나스닥: LBPH)이 2024년 2분기 재무 결과를 발표하고 2024년 8월 1일에 기업 업데이트를 제공할 것이라고 발표했습니다. 이번 업데이트에는 LP659에 대한 1상 단일 상승 용량(SAD) 초기 데이터가 포함될 예정이며, 이는 그들의 중심 작용, 고도로 선택적인 스핑고신-1-인산(S1P) 수용체 조절제입니다. 같은 날 오후 4시 30분 ET (오후 1시 30분 PT)에 콘퍼런스 콜과 웹캐스트가 열립니다.
투자자는 롱보드의 투자자 페이지의 이벤트 및 프레젠테이션 섹션을 통해 실시간 웹캐스트에 접근할 수 있습니다. 리플레이는 곧 이용 가능하며 최소 30일 동안 보관될 것입니다. 참여자는 제공된 링크와 회의 ID를 사용하여 웹캐스트 또는 전화 통화에 참여할 수 있습니다.
Longboard Pharmaceuticals (Nasdaq: LBPH) a annoncé qu'il publiera ses résultats financiers du deuxième trimestre 2024 et fournira une mise à jour d'entreprise le 1er août 2024. La mise à jour comprendra les données préliminaires de la Phase 1 sur des doses uniques en augmentation (SAD) pour LP659, leur modulateur sélectif des récepteurs de la sfingosine-1-phosphate (S1P) à action centrale. Un appel de conférence et un webinaire auront lieu à 16h30 ET (13h30 PT) le même jour.
Les investisseurs peuvent accéder au webinaire en direct dans la section Événements et Présentations de la page des investisseurs de Longboard. Un replay sera disponible peu après et archivé pendant au moins 30 jours. Les participants peuvent rejoindre via le webinaire ou par téléphone en utilisant les liens et l'ID de conférence fournis.
Longboard Pharmaceuticals (Nasdaq: LBPH) hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 veröffentlichen und am 1. August 2024 ein Unternehmensupdate bereitstellen wird. Das Update wird erste Phase-1-Daten zu einer jeweils steigenden Dosis (SAD) für LP659 enthalten, einen zentral wirkenden, hochselektiven Modulator des Sphingosin-1-Phosphat (S1P) Rezeptors. Am selben Tag findet um 16:30 Uhr ET (13:30 Uhr PT) eine Telefonkonferenz und ein Webcast statt.
Investoren können auf den Live-Webcast über den Bereich Veranstaltungen & Präsentationen auf der Investoren-Seite von Longboard zugreifen. Eine Aufzeichnung wird bald verfügbar sein und mindestens 30 Tage lang archiviert werden. Teilnehmer können entweder über den Webcast oder telefonisch teilnehmen, indem sie die bereitgestellten Links und die Konferenz-ID verwenden.
- Announcement of Q2 2024 financial results
- Presentation of topline Phase 1 SAD data for LP659
- Investor conference call and webcast scheduled
- None.
- Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers
- Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT)
Conference Call and Webcast Details
Longboard will host a conference call and webcast on August 1 at 4:30pm ET. Stockholders and other interested parties may participate in the call by following the instructions below. The live webcast can be accessed on the Events & Presentations portion of the investor page of Longboard’s website at https://ir.longboardpharma.com. A replay will be available on Longboard’s website shortly after completion of the event and will be archived for at least 30 days.
Participant Webcast Link: https://edge.media-server.com/mmc/p/qv83ogjy
Participant Dial-In:
CONFERENCE ID: 3710661
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age and older. Earlier this year, Longboard reported positive topline data from a Phase 1b/2a clinical trial (the PACIFIC Study) evaluating bexicaserin in participants with DEEs. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. Longboard recently completed a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Bexicaserin and LP659 are investigational compounds that are not approved for marketing by the FDA or any other regulatory authority.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. In some cases, you can identify forward-looking statements by words such as “to report”, “to be held”, “focused on”, “plan”, “will”, “may”, “can”, “working to”, “designed to”, “potential”, or the negative, plural or other tenses of these words, references to future dates or time periods, or other comparable language, and they include, without limitation, statements about the following: Longboard’s planned release of financial results, topline Phase 1 SAD data for LP659, and other corporate updates; Longboard’s planned conference call and webcast; Longboard’s focus and work; and Longboard’s product candidates, including their design, selectivity, and potential and Longboard’s plans for their future clinical development. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements include, but are not limited to, the following: the standard for Breakthrough Therapy designation is not the same as the standard for drug approval, the clinical evidence supporting Breakthrough Therapy designation is preliminary, and not all drugs designated as Breakthrough Therapies ultimately will be shown to have substantial improvement over available therapies; the FDA may later decide to rescind a Breakthrough Therapy designation if it determines the designation is no longer supported by subsequent data; Longboard’s product candidates are in the early phases of a lengthy research and development process, the timing, manner and outcome of research, development and regulatory review is uncertain, and Longboard’s product candidates, including bexicaserin and LP659, may not advance in research or development or be approved for marketing; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; topline or interim data may not accurately reflect the complete results of a particular study or trial and remain subject to audit, and final data may differ materially from topline or interim data; enrolling participants in clinical trials is competitive and challenging; risks related to unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Longboard or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; risks related to Longboard’s limited operating history, financial position and need for additional capital; Longboard will need additional managerial and financial resources to advance all of its programs, and you and others may not agree with the manner Longboard allocates its resources; risks related to the development and commercialization of Longboard’s product candidates; risks related to relying on licenses or collaborative arrangements; other risks related to Longboard’s dependence on third parties; competition; product liability or other litigation or disagreements with others; government and third-party payor actions, including relating to reimbursement and pricing; risks related to regulatory compliance; and risks related to Longboard’s and third parties’ intellectual property rights. Additional factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729804504/en/
CORPORATE CONTACT:
Megan E. Knight
VP, Head of Investor Relations
IR@longboardpharma.com
858.789.9283
Source: Longboard Pharmaceuticals, Inc.
FAQ
When will Longboard Pharmaceuticals (LBPH) report its Q2 2024 financial results?
What clinical data will Longboard Pharmaceuticals (LBPH) present in the August 1 update?
How can investors access Longboard Pharmaceuticals' (LBPH) Q2 2024 earnings call?
